Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized placebo-controlled double-blind study of upadacitinib in adults with active ankylosing spondylitis or non-radiographic axial spondyloarthritis
MOH_2020-05-11_008927Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of upadacitinib in ankylosing spondylitis (AS) and axial spondyloarthritis (axSpA) (4 arms), sponsored by AbbVie Inc. Started May 2020; status: completed.
02
Drugs
upadacitinib
03
Conditions
ankylosing spondylitis (AS)axial spondyloarthritis (axSpA)
Beyond the preview
Go deeper on MOH_2020-05-11_008927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-05-11_008927.